Emcure Pharmaceuticals Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Lakshit Sharma
- Category: Market
Emcure Pharmaceuticals share price Rs 1,833.10 (9 October 2026). Base target Rs 2,222, bull Rs 2,661, downside risk Rs 1,481. PE 34.47. 52W range Rs 1,306.50 to Rs 2,100.70.
Quick Answer
The Emcure Pharmaceuticals share price target for 2027 is Rs 2,222, about 21.2% above the current price of Rs 1,833.10. The bull case is Rs 2,661, and the downside risk level, which is not a target, is Rs 1,481. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 33.1%, with the stock holding its PE of 34.47. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing an Emcure Pharmaceuticals target price for 2027 should start with where the stock sits today. At Rs 1,833.10 on 9 October 2026, it is 12.7% below its 52-week high of Rs 2,100.70 and 40.3% above its 52-week low of Rs 1,306.50. That range spans 61% from low to high, so the entry point matters as much as the Emcure Pharmaceuticals price forecast itself.
This article builds the Emcure Pharmaceuticals share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 2,222 base case and the Rs 2,661 bull case were reached, along with a downside risk level of Rs 1,481.
Click Here – Get Free Investment Predictions
Emcure Pharmaceuticals Stock Analysis: Company Overview and Key Stats
Emcure Pharmaceuticals (NSE: EMCURE) has a market capitalisation of Rs 35,120 crore. In FY26 it reported revenue of Rs 9,335 crore and net profit of Rs 941.27 crore. The table collects the figures the Emcure Pharmaceuticals share price target is built on.
| Metric | Value |
|---|---|
| Company | Emcure Pharmaceuticals |
| NSE Ticker | EMCURE |
| CMP (9 October 2026) | Rs 1,833.10 |
| 52-Week High | Rs 2,100.70 |
| 52-Week Low | Rs 1,306.50 |
| Market Cap | Rs 35,120 crore |
| PE Ratio (TTM) | 34.47 |
| Industry PE | 37.59 |
| Price to Book | 7.09 |
| Return on Equity | 18.67% |
| Debt to Equity | 0.31 |
| EPS (TTM) | Rs 53.71 |
| Dividend Yield | 0.19% |
| 12-Month Base Target | Rs 2,222 |
| Bull Case | Rs 2,661 |
| Downside Risk Level (not a target) | Rs 1,481 |
Why Is Emcure Pharmaceuticals Share Price Target Set at Rs 2,222 for 2027?
The base-case Emcure Pharmaceuticals stock target of Rs 2,222 applies a PE multiple of 34.47 to a forward EPS estimate of Rs 64.45. That EPS assumes 20.0% yearly growth, the pace from FY24 to FY26, and puts the target 21.2% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Emcure Pharmaceuticals Target Price: Five Years of Results
Emcure Pharmaceuticals grew revenue from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew more slowly, from Rs 702.56 crore to Rs 941.27 crore (7.6% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 5,918.86 | 702.56 | 36.62 | 3.00 |
| FY23 | 6,031.72 | 561.85 | 29.42 | 2.00 |
| FY24 | 6,715.24 | 527.58 | 27.54 | 2.00 |
| FY25 | 7,968.78 | 707.47 | 36.43 | 3.00 |
| FY26 | 9,335.01 | 941.27 | 48.77 | 3.60 |
FY26 revenue growth was 17.1%, faster than the four-year average of 12.1%, and net profit moved up 33.0%. EPS rose from Rs 27.54 in FY24 to Rs 48.77 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Emcure Pharmaceuticals converted 10.1% of FY26 revenue into net profit, against 8.9% in FY25, within a five-year range of 7.9% to 11.9%. EBITDA margin was 19.8% in FY26 versus 19.2% in FY25.
In the June 2026 quarter, revenue was Rs 2,583 crore, up 22.7% from the same quarter a year earlier, while net profit of Rs 292.49 crore was up 36.2%. EBITDA came in at Rs 534.57 crore, up 27.1% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.31, and shareholders’ equity grew from Rs 2,114 crore in FY22 to Rs 4,977 crore in FY26. Operating cash flow in FY26 was Rs 943.55 crore against capital expenditure of Rs 547.69 crore, leaving free cash flow of Rs 395.86 crore, or 1.1% of the current market capitalisation. In FY25 free cash flow was Rs 444.78 crore.
Valuation Check for the Emcure Pharmaceuticals Stock Target: PE, Price to Book and ROE
At a PE of 34.47 against an industry PE of 37.59, Emcure Pharmaceuticals trades in line with its industry. Price to book is 7.09 on a book value of Rs 260.93 per share, and return on equity is 18.67%. A PE of 34.47 equals an earnings yield of 2.9%, and the FY26 dividend of Rs 3.60 per share gives a yield of 0.19%.
Shareholding Pattern and Institutional Holding
Promoters held 77.83% of Emcure Pharmaceuticals in June 2026, and promoter holding has stayed near 77.83% since June 2025. Foreign institutional investors (FII) held 4.88% and domestic institutions (DII) held 8.46%, which puts total institutional holding at 13.34%. FII holding rose from 2.86% in June 2025 to 4.88% in June 2026. Public shareholders own the remaining 8.83%.
Emcure Pharmaceuticals Share Price Targets for the Short Term and 12 Months
Short Term Emcure Pharmaceuticals Stock Target Levels: Technical Setup
At Rs 1,833.10 on 9 October 2026, Emcure Pharmaceuticals trades below its 50-day simple moving average of Rs 1,926.54 and above its 200-day exponential moving average of Rs 1,736.21. The 14-day RSI reads 17.3, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,926.54 (50-day simple moving average) and the nearest support is Rs 1,736.21 (200-day exponential moving average). A sustained move above Rs 1,926.54 would improve the short-term setup, while a close below Rs 1,736.21 would shift attention to the next support.
12 Month Emcure Pharmaceuticals Target Price for 2027
The 12-month target for Emcure Pharmaceuticals is Rs 2,222: forward EPS of Rs 64.45 at a PE of 34.47. That is 21.2% above Rs 1,833.10. It would also push the stock above its 52-week high of Rs 2,100.70.
How EPS Growth and PE Multiple Change the Emcure Pharmaceuticals Target Price
| EPS Growth | PE 27.58 | PE 34.47 | PE 39.64 |
|---|---|---|---|
| 0.0% (EPS Rs 53.71) | Rs 1,481 | Rs 1,851 | Rs 2,129 |
| 20.0% (EPS Rs 64.45) | Rs 1,778 | Rs 2,222 | Rs 2,555 |
| 25.0% (EPS Rs 67.14) | Rs 1,852 | Rs 2,314 | Rs 2,661 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Emcure Pharmaceuticals price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Emcure Pharmaceuticals Stock Target in 2027
Bull Case Rs 2,661
The bull case Emcure Pharmaceuticals price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 67.14, and a PE multiple that rises 15% to 39.64. That gives Rs 2,661, 45.2% above the current price and above the 52-week high of Rs 2,100.70, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,481
The downside risk level is not a target. It assumes EPS stays flat at Rs 53.71 and the PE falls 20% to 27.58. That gives Rs 1,481, 19.2% below the current price and above the 52-week low of Rs 1,306.50.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 39.64 | Rs 2,661 | +45.2% |
| Base Case | 20.0% | 34.47 | Rs 2,222 | +21.2% |
| Downside Risk | 0.0% | 27.58 | Rs 1,481 | -19.2% |
Key Risks to the Emcure Pharmaceuticals Target Price for 2027
Growth Slowdown Risk for the Emcure Pharmaceuticals Price Target
Revenue in the June 2026 quarter was up 22.7% year on year, and FY26 revenue growth was 17.1%. If growth slows from here, the EPS estimate behind the Emcure Pharmaceuticals stock target will need revising.
Liquidity and Size Risk
Emcure Pharmaceuticals has a market capitalisation of Rs 35,120 crore. Institutional holding is 13.34%, and promoters hold 77.83%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 10.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 34.47 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 27.58 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 12.7% below its 52-week high, with an RSI of 17.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in Emcure Pharmaceuticals
Start with the live price and volume. Any Emcure Pharmaceuticals share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 1,833.10 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Emcure Pharmaceuticals’ PE, ROE, debt and shareholding in one place.
Check Emcure Pharmaceuticals fundamentals on the Univest Screener
Then compare the three Emcure Pharmaceuticals target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals live price and get daily stock recommendations.
Conclusion
The Emcure Pharmaceuticals share price target for 2027 is Rs 2,222 in the base case, with Rs 2,661 as the bull case. The support for that view is arithmetic you can check: EPS grew 33.1% a year over FY24 to FY26, and the stock trades at a PE of 34.47. The risks are equally concrete, including a stock that sits 12.7% below its 52-week high and a downside scenario that cuts the price 19% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Emcure Pharmaceuticals Share Price Target 2027
What is the Emcure Pharmaceuticals share price target for 2027?
Ans. The base-case Emcure Pharmaceuticals share price target for 2027 is Rs 2,222, with Rs 2,661 as the bull case. The downside risk level, which is not a target, is Rs 1,481. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the Emcure Pharmaceuticals share price today?
Ans. As of 9 October 2026, 1:00 PM IST, Emcure Pharmaceuticals trades at Rs 1,833.10, down 0.99% on the day. The 52-week range is Rs 1,306.50 to Rs 2,100.70.
Is Emcure Pharmaceuticals a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 33.1% a year over FY24 to FY26, but the stock is 12.7% below its 52-week high. Whether Emcure Pharmaceuticals fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for Emcure Pharmaceuticals shares?
Ans. The bull case target is Rs 2,661, which assumes 25.0% EPS growth and a PE of 39.64. The downside risk level is Rs 1,481, which assumes flat EPS and a PE of 27.58. It marks a risk, not a target.
What are the main risks to the Emcure Pharmaceuticals price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 35,120 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of Emcure Pharmaceuticals and how does it compare with the industry?
Ans. The PE ratio of Emcure Pharmaceuticals is 34.47 against an industry PE of 37.59. Price to book is 7.09 and return on equity is 18.67%. The base case in the Emcure Pharmaceuticals price target holds this PE constant.
Who owns Emcure Pharmaceuticals, and what is the promoter holding?
Ans. Promoters held 77.83% of Emcure Pharmaceuticals in June 2026. FII held 4.88%, DII held 8.46% and the public held 8.83%.
What were Emcure Pharmaceuticals’ latest quarterly results?
Ans. In the June 2026 quarter, Emcure Pharmaceuticals reported revenue of Rs 2,583 crore (up 22.7% year on year) and net profit of Rs 292.49 crore (up 36.2%).